Wed, Jul 23, 2014, 8:40 AM EDT - U.S. Markets open in 50 mins.

Recent

% | $
Click the to save as a favorite.

pSivida Corp. Message Board

  • mickmack50 mickmack50 Sep 27, 2013 10:44 AM Flag

    UK Buzz Is ON!

    Regeneron's Eylea drug has phase III data available for DME, the same indication that Iluvien is seeking FDA approval for. This is an excerpt from the data release. FIVE monthly eye injections in a row, then, every two months after that? Wow, sign me up or go blind. Funny, Paul Ashton will be at the bio better conference next week. He'll present and the title will be "A SIMPLE ROUTE TO BIO-BETTERS". Now, the world might find that there is one, PSDV's Tethadur!

    In the VIVID-DME trial, after one year patients receiving EYLEA 2 mg monthly had a mean change from baseline in BCVA of 10.5 letters (p

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PSDV
4.380.00(0.00%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.